Total saponins from *Albizia julibrissin* inhibit vascular endothelial growth factor-mediated angiogenesis *in vitro* and *in vivo*

WEIWEI CAI¹, YUE LI¹, QINGQING YI¹, FENGSHAN XIE¹, BIN DU², LEI FENG² and LIYING QIU²

¹Laboratory of Natural Medicine, School of Pharmaceutical Science;  
²Laboratory of Tumor Pharmacology, Wuxi Medical School, Jiangnan University, Wuxi, Jiangsu 214122, P.R. China

Received March 2, 2014; Accepted December 9, 2014

DOI: 10.3892/mmr.2015.3228

**Abstract.** Dried stem bark from *Albizia julibrissin* (AJ) is a highly valued Traditional Chinese Medicine, which has been shown to suppress tumor growth and angiogenesis. Total saponins from AJ (TSAJ) are one of the most bioactive components of AJ extract. The present study evaluated the anti-tumor and anti-angiogenic effects of TSAJ *in vitro* and *in vivo*. The anti-angiogenic activity of TSAJ was investigated by measuring the effects on vascular endothelial growth factor (VEGF)-induced proliferation, migration and tube formation of Ea.hy926 endothelial cells *in vitro*. The expression levels of proteins associated with VEGF-induced angiogenesis were determined by western blotting. Furthermore, *in vivo* Matrigel™ plug and H22 hepatoma tumor models were used to verify the anti-angiogenic effects of TSAJ. The present study demonstrated that TSAJ significantly inhibited VEGF-mediated endothelial cell proliferation, migration and tube formation of Ea.hy926 cells *in vitro*. The anti-angiogenic effects of TSAJ were modulated by suppression of phosphorylated-(p-) focal adhesion kinase, p-Akt, and p-extracellular signal-regulated kinase in the VEGF/VEGF receptor 2 (R2) signaling pathway. Furthermore, oral administration of TSAJ significantly inhibited tumor growth and tumor-induced angiogenesis, as well as the formation of functional vessels, in the Matrigel™ plug model. These results suggest that TSAJ may be a potential anti-angiogenic agent that targets the VEGF/VEGFR2 signaling pathway, and inhibits tumor-induced angiogenesis.

**Introduction**

The concept that 'tumor growth is angiogenesis-dependent' was initially proposed by Folkman in 1971 (1), and suggests that the growth and metastasis of tumors depend on the development of blood vessels. In the early stages of cancer, the uncontrolled proliferation of cancer cells leads to a shortage of nutrients and oxygen, which causes a large degree of cell death (2,3). In response to the abnormal microenvironment, angiogenic molecules secreted by the tumor stimulate the formation of new functional vessels, from the pre-existing vasculature (4). Once the tumor cells acquire the ability to induce angiogenesis, tumor expansion is initiated, and tends to be malignant (5). Therefore, inhibiting the angiogenic process may be used as a potential therapy to prevent tumor growth and metastasis. Among the angiogenic factors, vascular endothelial growth factor-A165 (VEGF-A165, commonly referred to as VEGF) is positively associated with the proliferation, migration and tube formation of endothelial cells (6,7).

Upon VEGF binding to VEGF receptor 2 (R2), the main functional receptor tyrosine kinases of VEGF are activated, and a cascade of events are initiated, including the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) and RAF/MEK/ERK signaling pathways, which stimulate endothelial cell proliferation, migration and tube formation (8). Numerous studies have demonstrated that focal adhesion kinase (FAK), and its substrate paxillin, are involved in the signal transduction that participates in focal adhesion during cell migration (9-11).

*Albizia julibrissin* (AJ) (*Leguminosae*) is a Traditional Chinese Medicine that was recorded as an anti-inflammatory and sedative drug to treat swelling and pain in the lungs, shin ulcers, wounds and for the removal of carbuncles (12). In modern pharmacology, AJ exhibits marked inhibitory activity against certain cancer cell lines *in vitro* (13,14), which suggested that it may be used as an anti-tumor agent. In our previous study it was demonstrated that the crude extract of AJ exhibits anti-angiogenic effects on 3B11 and HMEC-1 cells (15). Further studies focused on the anti-angiogenic effects of AJ revealed that the active ingredients are the saponins. The total saponins from AJ (TSAJ), whose major
constituents include julibrose J, julibrose A, julibrose B1, julibrose C1, julibrose I, julibrose II and julibrose III (16-20), have been shown to possess anti-angiogenic and anti-tumor activities; however, the underlying mechanisms of action remain to be elucidated. The present study investigated the anti-angiogenic effects of TSAJ on VEGF-induced angiogenesis in vitro and in vivo, in order to explore the potential for TSAJ as an anti-tumor drug targeting the VEGF/VEGFR2 signaling pathway.

Materials and methods

Preparation of TSAJ. Dried stem barks from AJ (lot no. 201000154) were obtained from Zhejiang (China) and were identified by Professor Jian-wei Chen (Chinese Herbal Pharmacy, Nanjing University of Traditional Chinese Medicine, Nanjing, China). The voucher specimens were maintained in the herbarium stock room at the Laboratory of Natural Medicine, School of Pharmaceutical Science, Jiangnan University (Wuxi, China).

The TSAJ sample used in the present study was originally isolated from the AJ specimens. Briefly, the powder of AJ dried stem barks was extracted twice with 75% ethanol (reflux, 2.5 h each time) at 90°C. The ethanol extract was then evaporated, dissolved in deionized water and sequentially extracted with chloroform, ethyl acetate and n-butanol. The n-butanol fraction, which contained the most bioactive components, was dissolved in water and subjected to D101 macroporous resin (Tianjin Bohong Resin Technology, Tianjin, China) to yield 20% ethanol (20% E), 70% ethanol (70% E), 95% ethanol (95% E), and water components (Fig. 1).

Preliminary phytochemical screening of total saponins. The presence of saponins in the four fractions was assessed using foam and hemolytic tests.

Foam test. The four dried fractions (10 mg) were placed in a graduated cylinder with 10 ml distilled water. The suspension was shaken for 30 sec and a 2-3 cm layer of foam indicated the presence of saponins.

Hemolytic test. Once the hemaleucin in the anticoagulant whole blood of rabbit was discarded, the blood was washed three times with 0.9% normal sodium solution. Subsequently, the prepared erythrocytes were suspended in 0.9% saline solution to a final concentration of 2% (v/v). The solutions of the four fractions (1 ml) were separately added to the various erythrocyte suspensions (3 ml), and incubated at 37°C for 1 h. Normal sodium solution (0.9%) was used as a control. The hemolytic degree of the four fractions was assayed by observation. Briefly, following incubation, the mixtures were shaken for 30 sec and a 2-3 cm layer of foam indicated the presence of saponins (21).

Antibodies and other materials. Human VEGF-A165 was obtained from PeproTech, Inc. (Rocky Hill, NJ, USA). Matrigel™ was obtained from BD Biosciences (Franklin Lakes, NJ, USA). Rabbit polyclonal antibodies targeting β-tubulin (2148S), pY1175-VEGFR2 (2478S), pY570/Tyr577_Fak (3281S), pSer473-Akt (8200S) and pThr202/Thr204-extracellular signal-regulated kinase (Erk)1/2 (4370S) were purchased from Cell Signaling Technology (Danvers, MA, USA). Cluster of differentiation 31 (CD31) was purchased from Sangon Biotech Co., Ltd (Shanghai, China). Goat anti-rabbit immunoglobulin G (IgG) (H+L) horseradish peroxidase (HRP)-conjugated antibodies (21621) were purchased from EMD Millipore (Billerica, MA, USA). Reagents, including ethanol, chloroform, ethyl acetate, n-butanol, formalin and paraffin were purchased from China National Medicines Corporation (Beijing, China). Cell Counting kit-8 (CCK-8) was purchased from Beyotime Institute of Biotechnology (Haimen, China).

Animals. Female BALB/c mice (17-20 g) were purchased from the Research Center of Laboratory Animals (Hangzhou, China; grade specific-pathogen free and certificate no. SCXK (Zhe) 2008-0033). The mice were maintained in a barrier facility, in a temperature- and humidity-controlled environment, fed sterilized food and were given ad libitum access to water. Prior to the experiment, all of the mice were allowed to acclimate for one week. All experiments were conducted according to the Guides for the Care and Use of Laboratory Animals (Ministry of Science and Technology of China, 2006), and were approved by the Animal Ethics Committees of Jiangnan University (JN NO 20130327-0702).

Cell culture. The Ea.hy926 human endothelial cell line, generated from fusion of the A549 epithelial cell line with HUVEC, was provided by Professor Quan-sheng Zhou (Soochow University, Suzhou, China). The cells were cultured in cell medium consisting of Dulbecco's Modified Eagle Medium (DMEM; Hyclone Laboratories, Inc., Logan, UT, USA) supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), in 25 cm² culture flask at 37°C in an atmosphere containing 5% CO₂.

Determination of anti-angiogenic effects in vitro

Cell proliferation assay. The viability of the Ea.hy926 cells was assessed using a CCK-8. Briefly, the Ea.hy926 cells (6x10³ cells/well) were plated in 96-well plates (Corning, Inc., Corning, NY, USA) and cultured in normal growth medium for 24 h. The culture medium was then replaced with normal growth medium containing various concentrations of TSAJ (0, 0.78125, 1.5625, 3.125, 6.25, 12.5, 25, and 50 µg/ml), for 12, 24 and 48 h. Subsequently, the medium was replaced with DMEM containing 10% CCK-8. Following a 2 h incubation at 37°C, the absorbance of the resulting product was measured at a wavelength of 450 nm, using an ELISA microplate reader (Thermo Labsystems, Waltham, MA, USA). The percentage viability of the cells was then calculated using the following formula:

\[ \text{viability (\% of control)} = \left( \frac{\text{OD}_{\text{control}} - \text{OD}_{\text{treated}}}{\text{OD}_{\text{control}}} \right) \times 100 \]

ODControl and ODtreated represent the average OD450 value of cells in the control and TSAJ-treated groups, respectively. Three independent experiments were performed.

The effects of TSAJ on VEGF-induced cell viability were determined as described by previous methods (22). Briefly, the Ea.hy926 cells (6x10³ cells/well) were seeded in 96-well
cell plates and cultured in normal growth medium for 24 h. Subsequently, the cells were exposed to various concentrations of TSAJ (0, 0.78125, 1.5625, 3.125, 6.25, 12.5, 25, and 50 µg/ml), with or without VEGF (10 ng/ml), for 48 h in DMEM supplemented with 5% FBS. The medium was then replaced with DMEM containing 10% CCK-8. Following a 2 h incubation at 37˚C, the absorbance of the resulting product was measured at 450 nm, using an ELISA microplate reader (Labsystem, USA). The percentage viability of the cells was then calculated. At least three independent experiments were performed. The control group, which did not receive VEGF or TSAJ treatment, was set at 100%.

**Migration activity assay.** The migratory ability of the cells was assessed using a scratch-wound directional assay. Briefly, the Ea.hy926 cells were seeded at a cell density of 8x10^4 cells/well in a 24-well cell plate (Corning, Inc.), and grown overnight into a confluent monolayer. A sterile 20-200 µl micropipette tip (Axygen®; Corning Life Sciences, Tewksbury, MA, USA) was then used to create a ‘wound field’ of ±1000 µm width. The cells were washed twice with phosphate-buffered saline (Boster, Wuhan, China) and replaced in fresh medium containing the indicated concentrations of TSAJ, supplemented with 0.5% FBS and VEGF (10 ng/ml). Following a 14 h incubation, the migrated cells were photographed using an inverted microscope (TE2000-S; Nikon Corporation). Cell migration was estimated by measuring the endothelial cells that had migrated from the edge of the wounded monolayer (23). The percentage of migration was the mean calculated from five replicates of each experiment. Three independent experiments were performed. The control group, which did not receive VEGF or TSAJ treatment, was set at 100%.

**Tube formation assay.** The effects of TSAJ on the morphogenesis of endothelial cells were investigated using a capillary tube formation assay on Matrigel™. Briefly, the Matrigel™ was thawed at 4˚C overnight, and 80 µl was then added to a 96-well plate. Following a 45 min incubation at 37˚C, a cell density of 4x10^4 cells/well was seeded onto the Matrigel™-pre-coated 96-well plate. The cells were treated with TSAJ at 4.5 and 9 µg/ml, with or without VEGF (10 ng/ml). Following 6 h, tube formation was visualized and images were captured using an inverted microscope (TE2000-S; Nikon Corporation). Tube formation was quantified by counting the number of tubular structures within the capillary networks of five random fields (control group was set at 100%) using Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA). The results were the means calculated from five replicates of each experiment.

**Western blot analysis.** Protein expression levels were analyzed by western blot analysis, as previously described (24). Briefly, the 25 µg of total protein/well was loaded, following denaturing in loading buffer at 100˚C for 5 min. The protein extracts were then separated by 8-12% SDS-PAGE and electrophoretically transferred to nitrocellulose membranes (EMD Millipore). Subsequently, the membranes were blocked at room temperature for 2 h in 5% nonfat dry milk/Tris-buffered saline with Tween® (TBST). The membranes were then incubated at 4˚C overnight with various primary antibodies. The following day, the membranes were washed three times with TBST, and subsequently incubated with HRP-conjugated anti-rabbit IgG secondary antibodies, for 2 h at room temperature. Following the incubation, the membranes were washed with TBST, and the proteins bands were visualized using the Diaminobenzidine Detection system (Boster). β-tubulin was used as the protein loading control.

**Anti-angiogenic effects in vivo**

In vivo Matrigel™ plug assay. A Matrigel™ plug assay was performed in BALB/c mice, as described previously.
A. Preliminary phytochemical screening of total saponins. After phytochemical screening assays (foam and hemolytic tests) were conducted, the majority of saponins were contained in the ethyl acetate fraction of the 70% E (named TSAJ). with some modifications. (25). Briefly, female BALB/c mice (5-6 weeks old; weighing 17-20 g), were subcutaneously injected with 500 µl Matrigel™ containing heparin (130 U; Sigma-Aldrich) and mouse VEGF (250 ng). Mice injected with Matrigel™ and heparin alone were included as a vehicle control. The following day, the mice were orally administrated a single dose of saline, or TSAJ at 1.8 or 3.6 mg/kg; Sigma -Aldrich), and VEGF (250 ng). Mice injected with Matrigel™ and heparin alone were included as a vehicle control. Therefore, the effects of TSAJ on the tumor model had been established, the mice were randomly divided into three groups each containing 10 mice. The TSAJ-treated groups were orally administrated 1.8 mg/kg/d or 3.6 mg/kg/d of TSAJ. The vehicle control group was orally treated with the equivalent of 0.9% normal saline. Each dose was administered daily by oral gavage and the treatment lasted for 14 days. At the end of the experiment all the mice were sacrificed with an overdose of 10% chloral hydrate by intraperitoneal injection (400 mg/kg; Sigma-Aldrich), and the tumor tissue was segregated, weighed and photographed. The tumor inhibitory ratio was calculated using the following formula: Tumor inhibitory rate (%)=(W control–W treated)/W control x 100%. W control and W treated represent the average weights of the tumor in the vehicle control and TSAJ-treated groups, respectively.

The tumor samples were then formalin-fixed and paraffin-embedded. The sections (4 µm) were stained with hematoxylin and eosin (KeyGen BioTech, Nanjing, China), or immunostained with antibodies targeting mouse CD31 (1:100), p-ERK (1:200), p-AKT (1:200), and p-VEGFR2 (1:200). The immunostaining procedures were performed according to the manufacturer’s instructions. MVD was calculated using Image-Pro Plus 6.0 software.

**Statistical analysis.** All experiments were repeated three times. Data represent the mean ± standard error of the mean. Statistical significance was analyzed by unpaired Student’s t-test or one-way analysis of variance, using GraphPad v5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Preliminary phytochemical screening of total saponins.** In order to determine the existence of saponins among the four fractions of the A. julibrissin extract, traditional preliminary phytochemical screening assays (foam and hemolytic tests) were conducted. The majority of saponins were contained within 70% E (named TSAJ).

**TSAJ inhibits VEGF-induced viability of endothelial cells.** The inhibitory effects of TSAJ on cell viability in normal growth medium (containing 10% FBS) was initially evaluated using a CCK-8 assay. TSAJ inhibited cell viability in a dose- and time-dependent manner (Fig. 2A). When the Ea.hy926 cells were treated with 18 µg/ml TSAJ for 48 h, a significant inhibitory effect on viability was observed.

The present study also determined whether TSAJ inhibited VEGF-induced endothelial cell viability, at the same dose range. Stimulation with VEGF for 48 h increased the number of Ea.hy926 cells by ~2 fold (Fig. 2B). Treatment with TSAJ significantly suppressed the VEGF-induced increase in cell viability at doses from 9 µg/ml, in a dose-dependent manner. These results demonstrate that VEGF-activated endothelial cells were more sensitive to TSAJ, as compared with those cultured in normal growth medium, and that TSAJ may be a potent inhibitor of VEGF-induced increases in endothelial cell viability.

**TSAJ inhibits VEGF-induced migration of endothelial cells.** During angiogenesis, endothelial cell migration is an essential process. Therefore, the effects of TSAJ on the migratory ability of Ea.hy926 cells was determined using...
a wound-healing assay. VEGF significantly stimulated the directional migration of endothelial cells (Fig. 3A), and the number of migratory cells in the VEGF-treated group was >2 times more, as compared with the control group (Fig. 3B). The migratory rate of the TSAJ-treated endothelial cells was markedly suppressed, as compared with the VEGF-treated cells, and the inhibitory effects were more obvious at 9 µg/ml, as compared with at 4.5 µg/ml. These results suggest that TSAJ significantly suppressed VEGF-induced migration of endothelial cells in a dose-dependent manner.

**TSAJ inhibits VEGF-induced endothelial cell tube formation.** Angiogenesis is the formation of blood vessels from pre-existing vasculature, and is considered to be a complex process. During angiogenesis, the maturation of migrated endothelial cells into a capillary tube is a critical early step (27). Therefore, the present study investigated how TSAJ regulates capillary tube formation. Treatment with VEGF alone stimulated complete and robust tubular capillary structures (Fig. 4A). However, treatment with TSAJ massively disrupted the capillary tube network, and the tubes formed in the TSAJ-treated group were rather incomplete. In addition, the number of tubes formed was quantified using Image-Pro Plus software in low power field, and tube formation was shown to be negatively interrupted in response to treatment with TSAJ (Fig. 4B). These results demonstrate that TSAJ effectively inhibits VEGF-induced Ea.hy926 cell tube formation on Matrigel™ in a dose-dependent manner.

**TSAJ inhibits activation of the VEGFR2-mediated signaling pathway.** It is well known that the VEGF signaling pathway has a vital role in angiogenesis. VEGF binding to VEGFR2 results in the autophosphorylation of VEGFR2, which subsequently activates various downstream signaling molecules that are responsible for endothelial cell migration, proliferation and survival (28). To further elaborate the underlying mechanisms...
activation of

TSAJ in a

VEGF-202

VEGF

Akt (Ser)

counteracted by

dose-dependent manner (Fig. 5). In addition, TSAJ signifi-

cantly suppressed the VEGF-induced phosphorylations of

Akt, whereas activation of Erk1/2 mitogen-activated protein

kinases (MAPKs) is thought to be essential for VEGF-induced

survival of endothelial cells mainly through

VEGFR2-mediated signaling pathway. VEGF induces

tube formation assay.

angiogenesis 14 days after Matrigel

angiogenesis in vitro, therefore the

anti-angiogenic effects of TSAJ were subsequently validated

in vivo. The anti-angiogenic effects of TSAJ were evaluated in a

mouse Matrigel™ plug model, which is a powerful in vivo

angiogenesis assay (29). Matrigel™ plugs containing VEGF

alone were dark red, whereas the Matrigel™ plugs of the

TS AJ-treated group were light red (Fig. 6A). Conversely, the

Matrigel™ plugs of the vehicle group were avascular and pale

white. These superficial phenomena suggest that abundant

functional vasculatures had formed within the VEGF group,

whereas fewer blood vessels had formed within the Matrigel™

plugs of the TSAJ-treated group. To provide further evidence

for this finding, the number of functional vessels within the

Matrigel™ plugs were compared by M-T staining, which

stained the Matrigel™ blue and the endothelial cells/vessels

red (Fig. 6B). Fewer vessels were observed in the Matrigel™

plugs of the mice treated with VEGF and TSAJ, as compared

with those in the mice treated with VEGF alone (Fig. 6C).

These results demonstrate that TSAJ strongly suppresses

VEGF-induced angiogenesis 14 days after Matrigel™ implanta-
tion. These findings were concordant with the results of the

in vitro tube formation assay.

Anti-tumor effects of TSAJ on a H22 hepatoma cell transplanta-
tion model. Angiogenesis is the pivotal step in tumor growth and

metastasis, which provides necessary oxygen and nutri-

tents for the tumor (30). To investigate the anti-tumor effects of

TS AJ, a H22 hepatoma tumor model was generated.

Tumor growth was significantly suppressed by treatment

with TSAJ, at the dose of 3.6 mg/kg/d, after 14 days of treat-

ment (Fig. 7A). The tumors of the TSAJ-treated group were

significantly smaller, as compared with those in the control

group. The average tumor weight in the control group was

1.8 mg

kg

d, whereas the average tumor weight in the 3.6

kg

mg

VEGF group was 41.245% (Fig. 7C). These

results indicate that the rate of proliferation of tumor cells was

inhibited by TSAJ, in a dose-dependent manner.

Although tumor growth was indeed suppressed in response
to treatment with TSAJ, the anti-tumor mechanisms of TSAJ
still required further validation. To investigate new blood

vessel formation in solid tumors, immunostaining for CD31 was
performed (Fig. 7B). Microvessels were stained brown by CD31,
which is a specific-endothelial marker. The MVD

values in the TSAJ-treated groups were significantly reduced,
as compared with the control group (Fig. 7D). Furthermore,
treatment with TSAJ significantly decreased the expression

of the anti-angiogenic effects of TSAJ, the present study
evaluated some key signaling molecules involved in the

VEGFR2-mediated signaling pathway. VEGF induces

survival of endothelial cells mainly through activation of

Akt, whereas activation of Erk1/2 mitogen-activated protein

kinases (MAPKs) is thought to be essential for VEGF-induced

proliferation. VEGF-induced phosphorylation of VEGFR2

at Tyr-1175 was suppressed by treatment with TSAJ in a
dose-dependent manner (Fig. 5). In addition, TSAJ signifi-
cantly suppressed the VEGF-induced phosphorylations of

Akt (Ser177) and Erk (Thr202/Thr204). The effects of TSAJ on
the phosphorylation of FAK were also examined, and TSAJ

was shown to inhibit VEGF-induced phosphorylation of FAK,
when administered at a dose of 9 µg/ml. These results indicate
that TSAJ exerts its anti-angiogenic effects by selectively

targeting certain signaling events downstream of VEGFR2.

TSAJ inhibits VEGF-induced blood vessel formation in mice. The
results of the present study demonstrated that TSAJ effec-
tively inhibited VEGF-induced angiogenesis in vitro, therefore
the anti-angiogenic effects of TSAJ were subsequently validated
in vivo. The anti-angiogenic effects of TSAJ were evaluated in a
mouse Matrigel™ plug model, which is a powerful in vivo
angiogenesis assay (29). Matrigel™ plugs containing VEGF
alone were dark red, whereas the Matrigel™ plugs of the
TS AJ-treated group were light red (Fig. 6A). Conversely, the
Matrigel™ plugs of the vehicle group were avascular and pale
white. These superficial phenomena suggest that abundant
functional vasculatures had formed within the VEGF group,
whereas fewer blood vessels had formed within the Matrigel™
plugs of the TSAJ-treated group. To provide further evidence
for this finding, the number of functional vessels within the
Matrigel™ plugs were compared by M-T staining, which
stained the Matrigel™ blue and the endothelial cells/vessels
red (Fig. 6B). Fewer vessels were observed in the Matrigel™
plugs of the mice treated with VEGF and TSAJ, as compared
with those in the mice treated with VEGF alone (Fig. 6C).
These results demonstrate that TSAJ strongly suppresses
VEGF-induced angiogenesis 14 days after Matrigel™ implanta-
tion. These findings were concordant with the results of the
in vitro tube formation assay.

Anti-tumor effects of TSAJ on a H22 hepatoma cell transplanta-
tion model. Angiogenesis is the pivotal step in tumor growth and
metastasis, which provides necessary oxygen and nutri-
tents for the tumor (30). To investigate the anti-tumor effects of
TS AJ, a H22 hepatoma tumor model was generated.

Tumor growth was significantly suppressed by treatment
with TSAJ, at the dose of 3.6 mg/kg/d, after 14 days of treat-
ment (Fig. 7A). The tumors of the TSAJ-treated group were
significantly smaller, as compared with those in the control
group. The average tumor weight in the control group was
2.023±0.119 g, whereas the average tumor weight in the 3.6
kg
mg
mg
kg
mg
kg
mg
kg
VEGF group was 41.245% (Fig. 7C). These
results indicate that the rate of proliferation of tumor cells was
inhibited by TSAJ, in a dose-dependent manner.

Although tumor growth was indeed suppressed in response
to treatment with TSAJ, the anti-tumor mechanisms of TSAJ
still required further validation. To investigate new blood
vessel formation in solid tumors, immunostaining for CD31 was
performed (Fig. 7B). Microvessels were stained brown by CD31,
which is a specific-endothelial marker. The MVD

values in the TSAJ-treated groups were significantly reduced,
as compared with the control group (Fig. 7D). Furthermore,
treatment with TSAJ significantly decreased the expression

of the anti-angiogenic effects of TSAJ, the present study
evaluated some key signaling molecules involved in the

VEGFR2-mediated signaling pathway. VEGF induces

survival of endothelial cells mainly through activation of

Akt, whereas activation of Erk1/2 mitogen-activated protein

kinases (MAPKs) is thought to be essential for VEGF-induced

proliferation. VEGF-induced phosphorylation of VEGFR2

at Tyr-1175 was suppressed by treatment with TSAJ in a
dose-dependent manner (Fig. 5). In addition, TSAJ signifi-
cantly suppressed the VEGF-induced phosphorylations of

Akt (Ser177) and Erk (Thr202/Thr204). The effects of TSAJ on
the phosphorylation of FAK were also examined, and TSAJ

was shown to inhibit VEGF-induced phosphorylation of FAK,
when administered at a dose of 9 µg/ml. These results indicate
that TSAJ exerts its anti-angiogenic effects by selectively

targeting certain signaling events downstream of VEGFR2.
levels of p-VEGFR-2, p-Erk and p-Akt (brown-stained field), as compared with the control group (Fig. 7B). These results suggest that TSAJ is a potent angiogenic inhibitor, which inhibits tumor neovascularization and suppresses tumor growth through inhibition of the VEGFR-2 signaling pathway.

**Discussion**

In recent years, numerous efforts have been made to identify potential anti-angiogenic agents from traditional Chinese medicinal herbs. AJ has been used to treat various diseases for thousands of years (31); however, little is currently known with regard to the inhibitory effects of AJ on angiogenesis. Previous studies have reported that the chemical composition of AJ includes saponins, flavonoids, alkaloids and polysaccharides (32), and saponins are considered to be the main anti-tumor component (33). The present study explored the anti-angiogenic mechanisms of TSAJ. Angiogenesis depends on the proliferation, migration and tube formation of endothelial cells (34), and VEGF is a major proangiogenic factor that mediates these processes (35). The results of the present study demonstrated that VEGF significantly promoted the proliferation of Ea.hy926 cells. However, treatment with TSAJ resulted in a marked decrease in the VEGF-induced proliferation of Ea.hy926 cells, in a dose-dependent manner. Migration of endothelial cells as a response to pro-angiogenic factors is an integral feature of angiogenesis. The inhibitory effects of TSAJ in vitro were evaluated using a wound healing assay and a growth factor-reduced two-dimensional Matrigel™ model. In the two models, TSAJ inhibited the VEGF-induced cell migration and capillary tube formation of Ea.hy926 cells, thus suggesting that treatment with TSAJ suppressed VEGF-induced angiogenesis by restraining the cellular connection.

Angiogenesis stimulated by VEGF is a complex process. Upon binding to VEGF, VEGFR2 undergoes
autophosphorylation and transmits the signal to downstream molecules associated with angiogenic processes. The PI3K/Akt and RAF/MEK-ERK pathways are involved in VEGF-induced angiogenesis. The phosphorylation of VEGFR2 at Tyr-1175 is required for activation of Akt, which contributes to the proliferation and survival of endothelial cells (36). In addition, phosphorylation of VEGFR2 at Tyr-1175 activates the MAPK/ERK cascades, which also promote the proliferation of endothelial cells (36). FAK and its substrate paxillin are signaling molecules associated with VEGF-induced migration, which participate in focal adhesion during cell migration (37-39).

To elucidate the underlying anti-angiogenic mechanisms of TSAJ, the expression of signaling molecules and pathways were analyzed by western blotting. Treatment with TSAJ suppressed the phosphorylation of VEGFR2 at the Tyr1175 site in endothelial cells, suggesting that TSAJ may inhibit the kinase activity of VEGFR2 by downregulating the expression of VEGFR2. Furthermore, TSAJ significantly suppressed the VEGF-induced phosphorylation of Akt (Ser473) and Erk (Thr202/Thr204), in a dose-dependent manner. However, the phosphorylation of FAK was only markedly inhibited when the cells were treated with TSAJ at a dose of 9 µg/ml. These results suggest that TSAJ modulated VEGF-induced vascular permeability and angiogenesis by inhibiting the phosphorylation of VEGFR2, FAK, AKT, and ERK in endothelial cells.

The results of the present study demonstrated that TSAJ exhibits highly anti-angiogenic effects in vitro. In order to confirm the anti-angiogenic efficacy of TSAJ in an animal model, a mouse Matrigel™ plug assay was used. The Matrigel™ plug assay is a relatively quick and easy method to evaluate angiogenic and anti-angiogenic compounds (25). TSAJ markedly suppressed VEGF-induced neovascularization in the Matrigel™ plug assay, by inhibiting endothelial cell infiltration into the plug. The number of functional capillaries containing erythrocytes were markedly decreased in the TSAJ-treated group, as compared with the VEGF-induced group. These results suggest that TSAJ inhibited VEGF-induced neovascularization in the Matrigel™ plug assay, by inhibiting the invasion of endothelial cells.

Since the anti-angiogenic effects of TSAJ in vivo were validated using the Matrigel™ plug model, the H22 hepatoma tumor model was used to provide further evidence regarding the inhibitory effects. The hepatoma tumor model is widely used in the field of anti-tumor research (40). In the primary stages of tumor growth, tumor cells rapidly proliferate, and an abundance of nutrients and oxygen is required (41). Therefore, oxygen and nutrients, which are provided by tumor blood vessels, are considered to be critical factors to limit the growth of tumors. Once the formation of blood vessels is suppressed, tumor cells will undergo necrosis, due to ischemia and hypoxia (42,43). In response to hypoxia, vasculogenesis is induced by VEGF-A165, which is secreted by tumor cells and can improve the tumor microenvironment (7). Based on this concept, inhibition of angiogenesis may be an effective approach to prevent and treat cancer. In the present study, tumor growth was significantly inhibited in the TSAJ-treated group. Furthermore, the percentage of necrosis in the TSAJ-treated group was higher, as compared with that of the control group. Immunohistochemical staining with antibodies targeting CD31 demonstrated that the MVD was significantly decreased in the TSAJ-treated group, which limited the blood supply to the tumor. In addition, immunohistochemical staining showed that the expression of p-VEGFR2, p-Akt and p-Erk were significantly suppressed in the TSAJ-treated group. These signaling molecules are the main factors associated with the VEGF/VEGFR2 signaling pathway in angiogenesis of vascular endothelial cells. Therefore, downregulation of p-VEGFR2, p-Akt and p-Erk expression may be the underlying mechanism for the anti-angiogenic effects of TSAJ.

In conclusion, the present study was the first, to the best of our knowledge, to demonstrate that TSAJ is able to inhibit VEGF-induced endothelial cell proliferation, migration, and tube formation, by suppressing the activation of VEGFR2 and its downstream signaling of Fak, Akt and Erk in vitro and in vivo. Furthermore, the anti-angiogenic effects of TSAJ in vivo demonstrated that TSAJ may be considered as a potential oral anti-angiogenic drug, which targets the VEGF/VEGFR2 signal pathway.

Acknowledgements

The present study was supported by Fundamental Research Funds for the Central Universities (grant no. JUSRP51412B).

References

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-, 1971.
2. Wei A, Zhou D, Ruan J, Cai Y, Xiong C and Wu G: Anti-tumor and anti-angiogenic effects of Macrolythepteris viridifrons and its constituents by HPLC-DAD/MS analysis. J Ethnopharmacol 139: 373-380, 2012.
3. Rodriguez-Brenes IA, Komarova NL and Wodarz D: Tumor growth dynamics: insights into evolutionary processes. Trends Ecol Evol 28: 597-604, 2013.
4. Gacche RN and Meshram RJ: Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. Prog Biophys Mol Biol 1132, 333-354, 2013.
5. Makriilia N, Lappa T, Xyla V, Nikolaidis I and Syrigos K: The role of angiogenesis in solid tumours: an overview. Eur J Intern Med 20: 663-671, 2009.
6. Ellis LM and Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591, 2008.
7. Saharinen P, Eklund L, Pulkkki K, Bono P and Alitalo K: VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 17: 347-362, 2011.
8. Kang Z, Jiang W, Luan H, Zhao F and Zhang S: Cornin induces angiogenesis through PI3K-Akt-eNOS-VEGF signaling pathway. Food Chem Toxicol 58: 340-346, 2013.
9. Yoon H, Choi YL, Song JY, et al: Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines. PLoS One 9: e88587, 2014.
10. Lin SH and Shih YW: Antitumor effects of the flavone chalcone: inhibition of invasion and migration through the FAK/JNK signaling pathway in human gastric adenocarcinoma AGS cells. Mol Cell Biochem 391: 47-58, 2014.
11. Zhu J, Wang YS, Zhang J, et al: Focal adhesion kinase signaling pathway participates in the formation of choroidal neovascularization and regulates the proliferation and migration of choroidal microvascular endothelial cells by acting through HIF-1 and VEGF expression in RPE cells. Exp Eye Res 88: 910-918, 2009.
12. China Pharmacopoeia Committee (ed): Chinese Pharmacopoeia. Vol. 1. Chemical Industry Press, Beijing, p97, 2005.
13. Bou K, Zhao YY and Zhang RY: A cytotoxic saponin from Albizia julibrissin. Chem Pharm Bull (Tokyo) 54: 1211-1212, 2006.
14. Won HJ, Han CH, Kim YH, et al: Induction of apoptosis in human acute leukemia Jurkat T cells by Albizia julibrissin extract is mediated via mitochondria-dependent caspase-3 activation. J Ethnopharmacol 106: 383-389, 2006.
15. Liu LY, Du FF, Feng L and Qiu LY: Effect of different components from *Albizia julibrissin* on HMEC cells and 3B11 cells. Lishizhen Med Mater Med Res 22: 762-764, 2011.

16. Liang H, Tong WY, Zhao YY, Cui JR and Tu GZ: An antitumor compound julibrisside J28 from *Albizia julibrissin*. Bioorg Med Chem Lett 15: 4493-4495, 2005.

17. Zhou K, Zhao YY and Zhang Ry: Triterpenoid saponins from Cortex Albiziae. Journal of Practical Training of Medicine 36: 77-87, 2008.

18. Hua H, Feng L, Zhang XP, Zhang LF and Jin J: Anti-angiogenic activity of julibrisside J8, a natural product isolated from *Albizia julibrissin*. Phytochemistry 16: 703-711, 2009.

19. Zheng L, Zheng J, Zheng Q, Wang B, Yang Y and Wu L: Three new oleane triterpenoid saponins acetylated with monoperoxid acid from *Albizia julibrissin*. Fitoterapia 81: 859-863, 2010.

20. Jung YH, Ha RR, Kwon SH, et al: Anxiolytic effects of Julibrisside C1 isolated from *Albizia julibrissin* in mice. Prog Neuropsychopharmacol Biol Psychiatry 44: 184-192, 2013.

21. Zhou MH, Li JG, Wang RL, Liang CQ, Lu YL and Yang G: Experimental study on hemocytolysis of Rhizoma paridis total saponins. Chinese Journal of Cerebrovascular Diseases 18: 1611-1612, 2007.

22. Angulo J, Peir C, Romacho T, et al: Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by desbelsilate. Eur J Pharmacol 667: 153-159, 2011.

23. Pinkaew D, Cho SG, Hui DY, et al: Morelloflavone blocks injury-induced neointimal formation by inhibiting vascular smooth muscle cell migration. Biochim Biophys Acta 1790: 31-39, 2009.

24. Kim GD, Cheong OJ, Bae SY, Shin J and Lee SK: 6’-Debromohamacanthin A, a bis (indole) alkaloid, inhibits angiogenesis by targeting the VEGFR2-mediated PI3K/AKT/mTOR signaling pathways. Mar Drugs 11: 1087-1103, 2013.

25. Malinda KM: In vivo matrigel migration and angiogenesis assay. Methods Mol Biol 467: 287-294, 2009.

26. Sadanandam A, Rosenbaugh EG, Singh S, Varney M and Singh RK: Semaphorin 5A promotes angiogenesis by increasing endothelial cell proliferation, migration and decreasing apoptosis. Microvasc Res 79: 1-9, 2010.

27. Lai SL, Cheah SC, Wong PF, Noor SM and Mustafa MR: In vitro endothelial cell proliferation, migration and decreasing apoptosis. Methods Mol Biol 467: 287-294, 2009.

28. Pober JS and Sessa WC: Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 7: 803-815, 2007.

29. Adini A, Fainaru O, Udagawa T, Connor KM, Folkman J and D’Amato RJ: Matrigel cytometry: a novel method for quantifying angiogenesis in vivo. J Immunol Methods 342: 78-81, 2009.

30. Gomes FG, Nedel F, Alves AM, NR JE and Tarquinio SB: Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci 92: 101-107, 2013.

31. Tian WY, Ma CL, Liu F, Xia LH, Wang L and Wang JX: Research on the antineoplastic activity of the extract of alcoholized Albizia cortex in vivo of tumor-bearing mice. College 22: 5-6, 2000.

32. Yu DH, Qiao SY and Zhao YM: Advance in study on bark of *Albizia julibrissin*. 29: 619-624, 2004.

33. Li Q, Feng L, Shi J, Liu LY, Du B and Qiu LY: Screening of active substances of anti-angiogenesis induced by tumour cell in Albizia. Chin Tradit Pat Med 34: 744-747, 2012.

34. Goodwin AM: In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents. Microvasc Res 74: 172-183, 2007.

35. Zhao T, Zhao W, Chen Y, Ahokas RA and Sun Y: Vascular endothelial growth factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction. Microvasc Res 80: 188-194, 2010.

36. Holmqvist K, Cross MJ, Rolny C, et al: The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem 279: 22267-22275, 2004.

37. Zhao X and Guan J: Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev 63: 610-615, 2011.

38. Chen XL, Nam JO, Jean C, et al: VEGF-induced vascular permeability is mediated by FAK. Dev Cell 22: 146-157, 2012.

39. Lee J, Ku T, Yu H, et al: Blockade of VEGF-A suppresses tumor growth via inhibition of autocrine signaling through FAK and AKT. Cancer Lett 318: 221-225, 2012.

40. Wu Gao, Chen, et al: Anti-tumor effects of a novel chimeric peptide on S180 and H22 xenografts bearing nude mice. Peptides 31: 850-864, 2010.

41. Li Q, Fu GB, Zheng JT, et al: NAPDH oxidase subunit p22 (phox)-mediated reactive oxygen species contribute to angiogenesis and tumor growth through AKT and ERK1/2 signaling pathways in prostate cancer. Biochim Biophys Acta 1833: 3375-3385, 2013.

42. Burkovetskaya ME, Levin SG and Godukhin OV: Neuroprotective effects of interleukin-10 and tumor necrosis factor-alpha against hypoxia-induced hyperexcitability in hippocampal slice neurons. Neurosci Lett 416: 236-240, 2007.

43. Carloni S, Carnevali A, Cimino M and Balduini W: Extended role of necrotic cell death after hypoxia-ischemia-induced neurodegeneration in the neonatal rat. Neurobiol Dis 27: 354-361, 2007.